The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...
The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...
The drug Zepbound might not have the same name recognition as Ozempic, but it's another in the class to treat obesity and ...
Lisa Jarvis In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish ...
Two of President-elect Trump’s top health nominees are on a collision course as the incoming administration faces a crucial ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish ...
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s ...
While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback